- |||||||||| Ryzneuta (efbemalenograstim alpha) / Yifan Pharma
Journal: Efbemalenograstim Alfa-vuxw. (Pubmed Central) - Sep 9, 2024 A single fixed dose of 20 No abstract available
- |||||||||| Ryzneuta (efbemalenograstim alpha) / Yifan Pharma
Review, Journal: Efbemalenograstim Alfa: First Approval. (Pubmed Central) - Oct 22, 2023 Efbemalenograstim alfa is under regulatory review for the management of chemotherapy-induced neutropenia in the EU and the USA. This article summarizes the milestones in the development of efbemalenograstim alfa leading to this first approval for the management of chemotherapy-induced neutropenia.
- |||||||||| Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche, Bineuta (benegrastim) / Yifan Pharma
A Phase III, Randomized, Multi-Center, Open-Label, Fixed Dose, Neulasta Active-Controlled Clinical Trial of F-627, a Novel G-CSF, in Women with Breast Cancer Receiving Myelotoxic Chemotherapy () - Nov 24, 2021 - Abstract #ASH2021ASH_6558; Ryzneuta TM (F-627), a recombinant fusion protein containing human granulocyte-colony stimulating factor (G-CSF) and IgG2-Fc fragment, is intended to reduce CIN by utilizing the neutrophilic proliferating and activating properties of G-CSF...Methods - This was a phase III, multi-center, randomized, open-label, two-arm, active-controlled study that randomized female patients with Stage I to III invasive breast cancer who received 4 cycles of myelotoxic taxane + cyclophosphamide chemotherapy treatment...F-627 was well tolerated during the study with an overall safety profile comparable to that for Neulasta®. F-627 is a safe, effective, and easy to use alternative to current CIN therapy.
- |||||||||| Bineuta (benegrastim) / Yifan Pharma
Journal: Mechanism of C-type inactivation in the hERG potassium channel. (Pubmed Central) - Jan 31, 2021 Results suggest that C-type inactivation in hERG is associated with an asymmetrical constricted-like conformation of the selectivity filter, identifying F627 side-chain rotation and the hydrogen bond between Y616 and N629 as key determinants. Comparison of hERG with other K channels suggests that C-type inactivation depends on the degree of opening of the intracellular gate via the filter-gate allosteric coupling.
- |||||||||| Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche, Ryzneuta (efbemalenograstim alpha) / Yifan Pharma
Trial completion: Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy (clinicaltrials.gov) - Jul 17, 2020 P3, N=393, Completed, Comparison of hERG with other K channels suggests that C-type inactivation depends on the degree of opening of the intracellular gate via the filter-gate allosteric coupling. Active, not recruiting --> Completed
- |||||||||| Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche, Ryzneuta (efbemalenograstim alpha) / Yifan Pharma
Enrollment closed, Trial completion date: Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy (clinicaltrials.gov) - Jul 29, 2019 P3, N=393, Active, not recruiting, Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial completion date: Sep 2019 --> Mar 2020
|